Posted by Michael Wonder on 16 Apr 2019
Akcea steals march on Alnylam with NICE approval
16 April 2019 - Advantage to Tegsedi over Onpattro.
NICE has recommended Akcea Therapeutics’ rare disease treatment Tegsedi (inotersen), after the company improved its price offer.
The draft decision from NICE’s highly specialised technologies workstream is a major boost for Akcea, which was initially rejected in December alongside its close rival, Alnylam’s Onpattro (patisiran).
